Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 9Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Leukemia 3Squamous Cell Carcinoma of Head and Neck 1Meningioma 1Lung Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1Esophageal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Radiosurgery 12Temozolomide 10Radiotherapy 10Magnetic Resonance Spectroscopy 7Erlotinib Hydrochloride 6Bevacizumab 6Surgical Procedures, Operative 5Pemetrexed 5Gefitinib 5Drug Therapy 5Carboplatin 5pyrotinib 4icotinib 4aumolertinib 4Trastuzumab 3Spermine Synthase 3Radiation 3Lomustine 3Etoposide 3Dexmedetomidine 3Chlorotoxin 3Carmustine 3osimertinib 2camrelizumab 2apatinib 2Tyrosine Kinase Inhibitors 2Thiotepa 2Surveys and Questionnaires 2Sevoflurane 2Propofol 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Brain Neoplasms × Hydroxyurea × Clear all
NCT00904735 2013-08-12

Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma

National Cancer Institute (NCI)

Phase 2 Unknown
76 enrolled
CNS

Brain Neoplasms, Meningioma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡